MOPP versus ABVD and low-dose versus high-dose irradiation in hodgkin's disease at intermediate and advanced stages: Analysis of a meta-analysis by clinicians

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 730-732

  Andrieu, Jean Marie ^a   Yilmaz, Ugur ^a   Colonna, Pierre ^a  

^a Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABVD PROTOCOL; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; MOPP PROTOCOL; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HODGKIN DISEASE; HUMANS; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

EID: 0033071479     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Loeffler M, Brosteanu O, Hasenclever D, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16:818-829, 1998
2. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
3. Urba WJ, Longo DL: Hodgkin's disease. N Engl J Med 326:678-687, 1992
4. Kaplan HS: Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 26:1221-1224, 1966
5. Vijaykumar S, Myrianthopoulos LC: An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 24:1-13, 1992
6. Yelle L, Bergsagel D, Basco T, et al: Combined modality therapy of Hodgkin's disease: 10-year results of the National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. J Clin Oncol 9:1983-1993, 1991